Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab monotherapy versus placebo in adults with severe alopecia areata
NL-OMON60068Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alopecia areata comparing Amlitelimab with Placebo (2 arms). Primary endpoint: Change from baseline in SALT score. Started Oct 2024; status: completed.
02
Drugs
amlitelimab
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NL-OMON60068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60068.